In vitro assessment of nucleoside analogs in multiple myeloma

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 113-121

  Krett, Nancy L ^a   Ayres, Mary ^b   Nabhan, Chadi ^a,c   Ma, Chunguang ^a   Nowak, Billie ^b   Nawrocki, Steffan ^b   Rosen, Steven T ^a   Gandhi, Varsha ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

Gemcitabine; Multiple myeloma; Nucleoside analogs

Indexed keywords

ANTINEOPLASTIC AGENT; CLOFARABINE; CYTARABINE; FLUDARABINE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; GUANINE ARABINOSIDE; NUCLEOSIDE DERIVATIVE; TROXACITABINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 3843143965     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0777-2     Document Type: Article

References (48)

1. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484-489
2. Attal M, Haroussequ JL, Stoppa AM, Sotto JJ, Fuzibet JG, Fossi JF, Casaccus R, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 335:91-97
3. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′- diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879-1884
4. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995-1002
5. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB (1991) Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214
6. Gandhi V, Plunkett W (1990) Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680
7. Gandhi V, Plunkett W (2001) Combination strategies for purine nucleoside analogs. Marcel Dekker, New York
8. Gandhi V, Danhauser L, Plunkett W (1987) Separation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and 9-beta-D- arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-pressure liquid chromatography. J Chromatogr 413:293-299
9. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W (1996) Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 56:4453-4459
10. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W (1998) Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 13:839-848
11. Gazitt Y, Roodman D, Freytes C (2000) A phase I-II clinical trial with a combination of gemcitabine and paclitaxel for the treatment of refractory multiple myeloma patients (abstract no. 4984). Blood 96
12. Goldman-Leikin RE, Salwen HR, Herst CV, Variakojis D, Bian M, Lebeau M, Selvanayagan P, Marder R, Anderson R, Weitzman S, Rosen ST (1980) Characterization of a novel myeloma cell line. J Lab Clin Invest 113:335-345
13. Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R (1996) 2′,2′-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells 14:351-362
14. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
15. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031
16. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 38:567-572
17. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′- deoxycytidine). Cancer Res 50:4417-4422
18. Hjertner O, Borset M, Waage A (1996) Comparison of the effects of 2-chlorodeoxyadenosine and melphalan in myeloma cell lines. Leuk Res 20:155-160
19. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
20. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
21. Katarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R (1984) High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol 20:227-231
22. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 12:1527-1531
23. Kraut EH, Crowley JJ, Grever MR (1990) Phase II study of fludarabine phosphate in multiple myeloma. Invest New Drugs 8:199-200
24. Krenitsky TA, Tuttle JV, Koszalka GW, Chen IS, Beacham LM, Hideout JL, Elion GB (1976) Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem 251:4055-4061
25. Krett NL, Zell JL, Halgren RG, Pillay S, Traynor AE, Rosen ST (1997) Cyclic adenosine-3′,5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 3:1781-1787
26. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA (1995) 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 55:3352-3356
27. Lewis RA, Link L (1989) Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem Pharmacol 38:2001-2006
28. Lichman SM, Mittelman A, Budman DR, Puccio CA, Chun HG, Allen SL, Ahmed T, Arlin ZA (1991) Phase II trials of fludarabine phosphate in multiple myeloma using a loading dose and continuous infusion schedule. Leuk Lymphoma 6:61-63
29. Lund B, Kristjansen PE, Hansen HH (1993) Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55
30. Meinhardt G, Grun G, Dayyani F, Emmerich B, Schmidmaier R (2003) Gemcitabine is a potent inducer of apoptosis in multiple myeloma cells in vitro and has synergistic effects with modulators of protein kinase C. Blood 102:933a
31. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST (1992) A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 79:213-222
32. Nabhan C, Krett N, Gandhi V, Rosen S (2001) Gemcitabine in hematologic malignancies. Curr Opin Oncol 13:514-521
33. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST (2002) Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 1:1221-1227
34. Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM (1993) 2 Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 67:10-14
35. Offidani MA, Corvatta L, Marconi M, Malerba L, Olivieri A, Rupoli F, Alesiani F, Leoni P (2002) Gemcitabine alone or in combination with cisplatin in relapsed or refractory multiple myeloma. Leuk Lymphoma 43:1273-1279
36. Oken M (1992) New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma. Cancer 70:946-948
37. Parker WB, Cheng YC (1987) Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol 31:146-151
38. Plunkett W, Gandhi V (1997) Nucleoside analogs: cellular pharmacology, mechanisms of actions, and strategies for combination therapy. In: Cheson B, Keating MJ, Plunkett W (eds) Nucleoside analogs in cancer therapy. Marcel Dekker, New York, pp 1-36
39. Plunkett W, Gandhi V (2001) Purine and pyrimidine nucleoside analogs. Elsevier Science, Amsterdam
40. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10
41. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15
42. Rodriguez CO, Mitchell BS, Eriksson S, Gandhi V (2002) Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62:3100-3105
43. Shewach DS, Reynolds KK, Hertel L (1992) Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42:518-524
44. Spasokoukotskaja T, Arner ES, Brosjo O, Gunven P, Juliusson G, Liliemark J (1995) Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 31A:202-208
45. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
46. Wang L, Karlsson A, Arner ES, Eriksson S (1993) Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 268:22847-22852
47. Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B (2002) The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. Invest New Drugs 20:117-121
48. Xie C, Plunkett W (1995) Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55:2847-2852